

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Debnath, et al.	)	
		)	Examiner: Brian E. McDowell
Serial Number:	10/577,698	)	
		)	Group Art Unit: 1624
Filed:	April 28, 2006	)	
		)	Customer Number: 22827
Confirmation No.:	3725	)	
		)	Deposit Account: 04-1403
Title:	Novel Compounds and Their Use	)	
	in Medicine, as Antidiabetic and	)	
	Hypolipidemic Agents, Process	)	
	for Their Preparation and	)	
	Pharmaceutical Compositions	)	
	Containing Them	)	

**AMENDMENT**

Commissioner for Patents  
Post Office Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

Fee requirements (if any) have been calculated as shown below:

	Claims remaining after amendment		Highest number previously paid for		Present Extra		Additional Fee
Total Effective Claims	9	minus		=	0	X \$ 52 =	\$ <u>0.00</u>
Independent Claims	1	minus		=	0	X \$ 220 =	\$ <u>0.00</u>

- ☐ A Request for Continued Examination is requested in view of the: (\$810) \$ 0.00
- ☐ Previously submitted Amendment / Response dated \_\_\_\_\_
- ☐ Enclosed Amendment / Reply
- ☐ Enclosed Affidavit(s) / Declaration(s)
- ☐ Enclosed Information Disclosure Statement

Since Official Action set an original due date of \_\_\_\_\_,

**PETITION** is hereby made for an extension to cover the date this response is filed for which the requisite fee is enclosed (1 month \$130; 2 months \$490; 3 months \$1,110; 4 months \$1,730, 5 months \$2,350

\$ 0.00

If amendment enters proper multiple dependent claim(s) into this application for first time, add \$390.00 (per application)

\$ 0.00

If Terminal Disclaimer enclosed, add Rule 20(d) Official Fee (\$140.00)

\$ 0.00

Other: \_\_\_\_\_

\$ 0.00

**SUBTOTAL:**

\$ 0.00

If "small entity" verified statement filed ☐ previously,

☐ herewith, enter one-half (1/2) of subtotal and subtract

- \$ 0.00

**TOTAL FEE ENCLOSED:** \$ 0.00

The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof. This statement does not authorize charge of the issue fee in this case.

**DORITY & MANNING ATTORNEYS AT LAW, P.A.**

**ADDRESS:**

Post Office Box 1449  
Greenville, SC 29602 USA  
Customer ID No.: 22827  
Telephone: (864) 271-1592  
Facsimile: (864) 233-7342

By: Douglas L. Lineberry Reg. No: 54,274


Signature: 

Date: April 29, 2009

I hereby certify that this correspondence and all attachments and any fee(s) are being electronically transmitted via the internet to the U.S. Patent and Trademark Office using the Electronic Patent Filing System on April 29, 2009.

Tara W. Somers

(Typed or printed name of person transmitting documents)



(Signature of person transmitting documents)

**PATENT**

**ATTORNEY DOCKET NO: RED-18-PCT-US (DRF33029)**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application: Debnath, et al.	)	Examiner: Brian E. McDowell
	)	
Serial No: 10/577;698	)	Group Art Unit: 1624
	)	
Filed: April 28, 2006	)	Confirmation No: 3725
	)	
Title: Novel Compounds and Their Use	)	Account No: 04-1403
In Medicine, as Antidiabetic and	)	
Hypolipidemic Agents, Process	)	Customer No: 22827
For Their Preparation and	)	
Pharmaceutical Compositions	)	
Containing Them	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE TO 03/04/09 OFFICE ACTION**

Dear Sir:

In response to the Office Action dated March 4, 2009, please refer to the following remarks:

**Amendments to the Abstract** begin on page 2 of this paper.

**Amendments to the Claims** begin on page 3 of this paper.

**Remarks** begin on page 10 of this paper.